[144] Bicara Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Bicara Therapeutics, Inc. (BCAX) filed a Form 144 notifying a proposed sale of 6,514 common shares, with an aggregate market value of $110,998, listing the intended sale date as 10/06/2025 on NASDAQ. The filing shows these shares were acquired and paid for on 10/06/2025 through the exercise of stock options from the issuer, with payment in cash. The filer reports no securities sold in the prior three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Positive

• Acquisition via exercise of options (same day), showing shares were obtained through an authorized compensation mechanism
• Small size relative to outstanding shares: 6,514 vs 54,562,841 outstanding, limiting immediate market impact

Negative

• Proposed sale by insider of 6,514 shares valued at $110,998 could be perceived as liquidity need or portfolio rebalancing
• Filer identity not visible in the provided text, requiring verification of the actual registrant/insider on EDGAR

Insights

Insider Transactions Analyst

Small insider sale follows same‑day option exercise; watch for routine liquidity.

The notice shows an insider exercised options and immediately intends to sell 6,514 shares valued at $110,998 on 10/06/2025, which is a common way for option holders to cover exercise costs and taxes. This transaction size is a small fraction of the reported outstanding shares (54,562,841), so the direct dilution or market impact is limited.

Key dependencies include whether the seller is a named executive or significant holder and whether additional scheduled sales follow; if none are disclosed, near‑term market effect is likely muted. Monitor public filings for any subsequent Form 4s or additional 144 notices within the next 30–90 days.

Corporate Compliance Specialist

Form 144 appears procedurally complete but contains minimal detail on filer identity.

The filing records the broker (UBS Financial Services) and confirms cash payment for option exercise on 10/06/2025, and indicates no sales in the past three months. The standard attestation about absence of undisclosed material adverse information is included, fulfilling Rule 144 procedural elements.

Because the document omits the filer name/CIK in the visible fields, verify the official EDGAR submission for the filer identity and any related Form 4 to confirm compliance and timing. Expect any compliance follow‑up filings within days if the sale executes.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	6514	110998.00	54562841	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/06/2025	Exercise of stock options	Issuer			6514	10/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Bicara Therapeutics (BCAX) disclose in this Form 144?

The filing notifies a proposed sale of 6,514 common shares valued at $110,998, acquired and to be sold on 10/06/2025 via exercise of stock options with payment in cash.

When is the proposed sale of BCAX shares scheduled?

The Form 144 lists the approximate date of sale as 10/06/2025 on NASDAQ.

How large is the sale relative to Bicara’s outstanding shares?

The proposed sale is 6,514 shares versus 54,562,841 shares outstanding, a very small fraction of the total share count.

How were the shares acquired before the proposed sale?

The shares were acquired on 10/06/2025 by exercise of stock options from the issuer, with payment made in cash.

Does the filing indicate prior sales by the same person in the past three months?

No; the section for securities sold during the past three months states "Nothing to Report".